PathWhiz

PathWhiz ID	Pathway	Meta Data
PW146022 View Pathway	drug action Iopromide Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:13 Last Updated: October 07, 2023 at 17:13
PW176564 View Pathway	metabolic Iopromide Predicted Metabolism Pathway Homo sapiens Metabolites of Template6MB2 are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 14, 2023 at 13:41 Last Updated: December 14, 2023 at 13:41
PW146002 View Pathway	drug action Iothalamic acid Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:10 Last Updated: October 07, 2023 at 17:10
PW176072 View Pathway	metabolic Iothalamic acid Predicted Metabolism Pathway new Homo sapiens Metabolites of Iothalamic acid are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 13:43 Last Updated: November 29, 2023 at 13:43
PW146168 View Pathway	drug action Iotrolan Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:34 Last Updated: October 07, 2023 at 17:34
PW146003 View Pathway	drug action Ioversol Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:10 Last Updated: October 07, 2023 at 17:10
PW128511 View Pathway	metabolic Ioversol Metabolism Homo sapiens The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary. The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool. Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. Ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose. Ioversol does not undergo significant metabolism, deiodination or biotransformation. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: September 01, 2023 at 09:52 Last Updated: September 01, 2023 at 09:52
PW176073 View Pathway	metabolic Ioversol Predicted Metabolism Pathway new Homo sapiens Metabolites of Ioversol are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 13:44 Last Updated: November 29, 2023 at 13:44
PW146080 View Pathway	drug action Ioxaglic acid Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:21 Last Updated: October 07, 2023 at 17:21
PW128501 View Pathway	metabolic Ioxaglic acid Metabolism Homo sapiens Ioxaglic acid is an iodine-containing, low osmolality contrast agent. Ioxaglate is a molecule that consists of six iodine atoms and achieves water solubility by ionization; thus, it is a 3.0 ratio ionic agent. The low-osmolality of ioxaglic acid reduces the risk of adverse events. The occurrence of adverse reactions is more common after the use of high-osmolarity agents: about 15% with a high-osmolarity agent versus 3% with a low-osmolarity agent. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: August 31, 2023 at 20:32 Last Updated: August 31, 2023 at 20:32